UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy
UniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the Trump administration is relaxing its previous hard-line stance on drug reviews.
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.